Elixiron Immunotherapeutics was founded in April 2017 with initial seed funding from a private angel investor group followed by Series A funding from a VC consortium led by Taiwania Capital, with $16.5M total capital raised as of January 2020. Investment and partnership interest to bring our promising therapeutics candidates to patients or to discuss new opportunities is welcome - Contact Us
Elixiron Immunotherapeutics
3 Park Street, 17th Floor, Taipei City 11503, Taiwan
Elixiron Immunotherapeutics (China) Ltd
No.1 South Building, 5th Floor, JinChuang Mansion, 4560 Jinke Rd, Shanghai 201210, China
Investor inquiries: investors@elixiron.com
Media inquiries: media@elixiron.com
Careers and general inquiries: info@elixiron.com